Overview Dividends

(ELAN) Elanco Animal Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28414H1032

Parasiticides, Vaccines, Therapeutics, Antibiotics, Feed Additives

ELAN EPS (Earnings per Share)

EPS Growth (3Y CAGR): -58.55%
EPS Trend (3Y Correlation): -25.0%

ELAN Revenue

Revenue Growth (3Y CAGR): 7.16%
Revenue Trend (3Y Correlation): 38.1%

Description: ELAN Elanco Animal Health November 03, 2025

Elanco Animal Health (NYSE: ELAN) develops, manufactures and markets a broad portfolio of veterinary products for companion animals and livestock. Its pet-care line includes parasiticides, vaccines and therapeutics sold under brands such as Seresto, Advantix, Credelio, Galliprant and Atopica, while its farm-animal segment offers medicated feed additives, injectable antibiotics, vaccines and insecticides for cattle, swine and poultry (e.g., Rumensin, Baytril, Maxiban, AviPro). Distribution is a mix of third-party wholesalers, independent retailers and direct sales to veterinarians and producers.

Key metrics that shape Elanco’s outlook include FY 2023 revenue of roughly $3.2 billion, with the pet-health segment contributing about 55 % and delivering a 12 % YoY growth rate driven by rising pet ownership and premiumization trends in the United States and Europe. The livestock business is sensitive to global protein demand; a 5 % annual increase in meat consumption in emerging markets is a primary growth driver, while feed-cost inflation and regulatory scrutiny on antibiotic use pose margin pressures. Elanco’s R&D pipeline, highlighted by next-generation parasiticides and a pipeline of novel biologics for dairy cattle, is expected to sustain product-launch momentum over the next 12-24 months.

For a deeper, data-driven valuation of ELAN, you may find ValueRay’s analyst toolkit useful for quantifying these drivers and testing scenario outcomes.

ELAN Stock Overview

Market Cap in USD	11,004m
Sub-Industry	Pharmaceuticals
IPO / Inception	2018-09-20

ELAN Stock Ratings

Growth Rating	42.5%
Fundamental	49.6%
Dividend Rating	-
Return 12m vs S&P 500	30.0%
Analyst Rating	3.87 of 5

ELAN Dividends

Currently no dividends paid

ELAN Growth Ratios

Growth Correlation 3m	94.4%
Growth Correlation 12m	72.2%
Growth Correlation 5y	-61.7%
CAGR 5y	16.90%
CAGR/Max DD 3y (Calmar Ratio)	0.30
CAGR/Mean DD 3y (Pain Ratio)	0.81
Sharpe Ratio 12m	-0.08
Alpha	43.05
Beta	1.649
Volatility	39.45%
Current Volume	6644.7k
Average Volume 20d	5202k
Stop Loss	20.7 (-3.7%)
Signal	0.84

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (434.0m TTM) > 0 and > 6% of Revenue (6% = 269.0m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -0.50pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 49.55% (prev 58.79%; Δ -9.24pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 572.0m > Net Income 434.0m (YES >=105%, WARN >=100%)

Net Debt (3.67b) to EBITDA (1.53b) ratio: 2.40 <= 3.0 (WARN <= 3.5)

Current Ratio 2.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (500.1m) change vs 12m ago 1.19% (target <= -2.0% for YES)

Gross Margin 42.98% (prev 43.12%; Δ -0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 32.60% (prev 32.64%; Δ -0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.20 (EBITDA TTM 1.53b / Interest Expense TTM 270.0m) >= 6 (WARN >= 3)

Altman Z'' 0.73

(A) 0.16 = (Total Current Assets 3.61b - Total Current Liabilities 1.39b) / Total Assets 13.74b

(B) -0.14 = Retained Earnings (Balance) -1.87b / Total Assets 13.74b

(D) -0.30 = Book Value of Equity -2.06b / Total Liabilities 6.97b

Total Rating: 0.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 49.62

1. Piotroski 4.50pt = -0.50

2. FCF Yield 2.42% = 1.21

3. FCF Margin 7.92% = 1.98

4. Debt/Equity 0.62 = 2.31

5. Debt/Ebitda 2.40 = -0.78

6. ROIC - WACC (= -5.42)% = -6.77

7. RoE 6.74% = 0.56

8. Rev. Trend 38.13% = 2.86

9. EPS Trend -25.02% = -1.25

What is the price of ELAN shares?

As of November 08, 2025, the stock is trading at USD 21.49 with a total of 6,644,717 shares traded.
Over the past week, the price has changed by -2.98%, over one month by +5.09%, over three months by +30.40% and over the past year by +48.21%.

Is Elanco Animal Health a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Elanco Animal Health (NYSE:ELAN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 49.62 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ELAN is around 20.83 USD . This means that ELAN is currently overvalued and has a potential downside of -3.07%.

Is ELAN a buy, sell or hold?

Elanco Animal Health has received a consensus analysts rating of 3.87. Therefore, it is recommended to buy ELAN.

Strong Buy: 6
Buy: 1
Hold: 8
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ELAN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	21.6	0.3%
Analysts Target Price	21.6	0.3%
ValueRay Target Price	23.3	8.5%

ELAN Fundamental Data Overview November 04, 2025

Market Cap USD = 11.00b (11.00b USD * 1.0 USD.USD)
P/E Trailing = 25.1705
P/E Forward = 20.5339
P/S = 2.4542
P/B = 1.5011
P/EG = 8.9357
Beta = 1.649
Revenue TTM = 4.48b USD
EBIT TTM = 863.0m USD
EBITDA TTM = 1.53b USD
Long Term Debt = 4.15b USD (from longTermDebt, last quarter)
Short Term Debt = 61.0m USD (from shortTermDebt, last quarter)
Debt = 4.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.67b USD (from netDebt column, last quarter)
Enterprise Value = 14.67b USD (11.00b + Debt 4.21b - CCE 539.0m)
Interest Coverage Ratio = 3.20 (Ebit TTM 863.0m / Interest Expense TTM 270.0m)
FCF Yield = 2.42% (FCF TTM 355.0m / Enterprise Value 14.67b)
FCF Margin = 7.92% (FCF TTM 355.0m / Revenue TTM 4.48b)
Net Margin = 9.68% (Net Income TTM 434.0m / Revenue TTM 4.48b)
Gross Margin = 42.98% ((Revenue TTM 4.48b - Cost of Revenue TTM 2.56b) / Revenue TTM)
Gross Margin QoQ = 46.49% (prev 46.61%)
Tobins Q-Ratio = 1.07 (Enterprise Value 14.67b / Total Assets 13.74b)
Interest Expense / Debt = 1.66% (Interest Expense 70.0m / Debt 4.21b)
Taxrate = 56.00% (14.0m / 25.0m)
NOPAT = 379.7m (EBIT 863.0m * (1 - 56.00%))
Current Ratio = 2.60 (Total Current Assets 3.61b / Total Current Liabilities 1.39b)
Debt / Equity = 0.62 (Debt 4.21b / totalStockholderEquity, last quarter 6.78b)
Debt / EBITDA = 2.40 (Net Debt 3.67b / EBITDA 1.53b)
Debt / FCF = 10.34 (Net Debt 3.67b / FCF TTM 355.0m)
Total Stockholder Equity = 6.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.16% (Net Income 434.0m / Total Assets 13.74b)
RoE = 6.74% (Net Income TTM 434.0m / Total Stockholder Equity 6.44b)
RoCE = 8.15% (EBIT 863.0m / Capital Employed (Equity 6.44b + L.T.Debt 4.15b))
RoIC = 3.53% (NOPAT 379.7m / Invested Capital 10.76b)
WACC = 8.95% (E(11.00b)/V(15.21b) * Re(12.09%) + D(4.21b)/V(15.21b) * Rd(1.66%) * (1-Tc(0.56)))
Discount Rate = 12.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.74%
[DCF Debug] Terminal Value 54.64% ; FCFE base≈383.0m ; Y1≈251.5m ; Y5≈115.0m
Fair Price DCF = 2.71 (DCF Value 1.35b / Shares Outstanding 496.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -25.02 | EPS CAGR: -58.55% | SUE: -3.19 | # QB: 0
Revenue Correlation: 38.13 | Revenue CAGR: 7.16% | SUE: 4.0 | # QB: 2

Additional Sources for ELAN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle